//THE ONLINE ONCOLOGIST
Society of Gynecologic Oncologists The Society of Gynecologic Oncologists (SGO) is a national organization for healthcare professionals who treat women with gynecologic cancers. By becoming a member of SGO, oncologists can access the SGO website’s practice management tools, clinical guidelines, clinical data, practice resources, and more. Members with subscriptions can also access the SGO journal Gynecologic Oncology online and earn CME credit for reviewing manuscripts submitted to the journal. Other features of the SGO website include an e-learning center, coding and reimbursement workshop, surgical education section, bookstore, relevant news articles, and information on upcoming gynecologic oncology conferences and meetings. Another section of the SGO website focuses on government relations and has a legislative action center and sections on position statements, regulatory and legislative issues, and healthcare reform implementation.http://sgo.org//THE EDUCATED PATIENT®
Ovarian Cancer National Alliance The Ovarian Cancer National Alliance (OCNA) is an advocacy group for persons with ovarian cancer. On the OCNA website, visitors can access an “About Ovarian Cancer” section featuring an ovarian cancer overview and pages on ovarian cancer statistics, risk factors, detection, treatment, symptoms, and FAQs. The OCNA launched a periodical in September, The Teal Journal, which is designed to explain to patients the latest scientific findings and how they impact the ovarian cancer community. The clinical trials section of the website explains how to find a clinical trial, the various types of trials, barriers to clinical trials, and common questions and concerns. This section also offers a list of resources on clinical trials. Other features on the OCNA website include a glossary of ovarian cancer terms, symptom diary, and educational webinar series.www.ovariancancer.org//ONLINE CMEMaking the best of PARP inhibitors in ovarian cancerCredits:
: August 10, 2011
This CME activity focuses on how poly(ADP-ribose) polymerase (PARP) inhibitors can be used in the treatment of ovarian cancer, especially in cancers with mutations in the BRCA1 or BRCA2 tumor suppressors. The first sections review BRCA1 and BRA mutations in ovarian cancer, the response of BRCA carriers to therapy, and BRCA1 and BRA in DNA repair. The next part focuses on PARP inhibitors, specifically the synthetic lethality of PARP inhibitors, resistance to PARP inhibitors, recent clinical studies with PARP inhibitors, and an integrated approach to PARP inhibition. The final sections of the CME activity discuss the timing of treatment, identifying the target population, and the authors’ conclusions. After completing the activity, participants should be able to distinguish the characteristics of BRCA-associated ovarian cancer, recognize how BRCA mutations affect the response to therapy for advanced ovarian cancer, and review the efficacy and safety of PARP inhibitors in the treatment of ovarian cancer based on recent research, and including the limitations in current studies.http://tinyurl.com/3x3v77w//eABSTRACT
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neoadjuvant chemotherapyJournal:
The Quarterly Journal of Nuclear Medicine and Molecular Imaging Authors: Martoni AA, Fanti S, Za- magni C, et alPurpose:
The standard duration of neoadjuvant chemotherapy (na- CHT) prior to debulking surgery for advanced ovarian cancer is 3 courses. The authors of this study hypothesized that some patients may benefit from additional courses, and that [18F]FDG-PET/CT monitoring during na-CHT could predict early pathological response, enabling phy- sicians to deliver an optimal duration of na-CHT. For this study, patients with advanced ovarian cancer who were unsuitable for optimal upfront surgery but were fit for na-CHT were monitored using FDG-PET/CT at baseline and after 3 and 6 courses of carboplatin-paclitaxel CHT. At the end of na-CHT, patients were re- evaluated for definitive optimal surgery. Percentage changes in maximal standardized uptake value were then compared with pathological response. Patients with pathological complete response or minimal residual disease were classified as pathological re- sponders (pRs); all other cases were classified as non-responders (NRs).